Table 2.

N-gly sites identified in the major clone of 6 patients with FL taken at different time points of disease

Patient	Disease event	No. of N-gly sites	Region in IGHV	AA position of N-gly site	N-gly motif in major clone	Percentage of unique subclones with N-gly site of major clone present
1	Diagnosis	1	CDR3	108	NFS	98.31
	Transformation	1	CDR3	108	NVS	98.17
2	1st relapse	4	CDR1, FR2, CDR2, FR3	30, 39, 56, 85	NFS, NMS, NIT, NNS	99.01, 99.01, 98.87, 97.22
	3rd relapse	4	CDR1, FR2, CDR2, FR3	30, 39, 56, 85	NFS, NMS, NIT, NNS	99.31, 96.8, 98.75, 81.83
	Transformation	4	CDR1, FR2, CDR2, FR3	30, 39, 56, 85	NFS, NMS, NIT, NNT	98.54, 98.16, 97.71, 84.95
3	2nd relapse	1	CDR2	56	NIS	97.47
	3rd relapse	1	CDR2	56	NIS	97.91
	Transformation	1	CDR2	56	NIS	98.18
4	1st relapse	2	FR2, CDR3	48, 108	NKS, NNS	97.53, 100
	2nd relapse	2	FR2, CDR3	48, 108	NKS, NNS	97.98, 99.6
5	1st relapse	1	CDR1	30	NFS	97.14
	3rd relapse	1	FR3	94	NLT	99.19
6	FL diagnosis	1	CDR3	108	NGS	98.41
	tFL diagnosis	1	CDR3	108	NGS	97.94
	tFL relapse	1	CDR3	108	NGS	96.74

Italic text in bold refers to differences in the location or amino acid (aa) sequence of N-gly sites, referred to as N-gly motif, within the major clone across temporal samples. The major clone was determined by the highest count number. The multiple values in patient 2 and 4 relate to the multiple N-gly sites observed. The majority of subclones across patients and disease events retain the N-gly site of the major clones (P < .0001). AA, amino acid. Numbers given under the heading “AA position of N-gly site” refer to the position of the middle AA making up the N-gly site, according to IMGT numeration of the variable region.